Verrica Pharmaceuticals Inc (VRCA)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Verrica Pharmaceuticals Inc chart...

About the Company

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.

CEO

Ted White

Exchange

NASDAQ

Website

http://www.verrica.com/

$5M

Total Revenue

31

Employees

$204M

Market Capitalization

-4.19

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VRCA News

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?

16d ago, source:

We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears ...

Verrica Pharmaceuticals Inc VRCA

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

18d ago, source: Seeking Alpha

Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Fourth Quarter and Year End 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is ...

Verrica Pharmaceuticals Set to Discuss Q4 and Full-Year 2023 Financial Results in Upcoming Conference Call

22d ago, source: Hosted on MSN

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a trailblazing company in the field of dermatology therapeutics, has announced it will host a conference call and live webcast at ...

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

19d ago, source: Business Insider

Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical ...

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

18d ago, source: Stockhouse

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin ...

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

18d ago, source: WIVB-TV

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing ...

Verrica Pharmaceuticals Inc VRCA

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results

19d ago, source: Yahoo Finance

Fourth Quarter Revenue: Verrica Pharmaceuticals Inc (NASDAQ:VRCA) reported YCANTH revenue of $1.9 million. Full-Year Revenue: Full-year revenue for YCANTH totaled $4.7 million. Insurance Coverage ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...